Why the study?
How can drug-drug interactions between small-molecule inhibitors and direct oral anticoagulants be prevented in patients with nonsmall cell lung cancer?
How can drug-drug interactions between small-molecule inhibitors and direct oral anticoagulants be prevented in patients with nonsmall cell lung cancer?
Drug-drug interactions between small-molecule inhibitors and DOACs in nonsmall cell lung cancer patients can be managed by dosage adjustment, administration separation, or switching anticoagulants.
Answers are grounded in this paper and cite their sources.
Requires DDI assessment when combining SMIs with DOACs in NSCLC; extends oncology anticoagulation guidance with practical mitigation strategies.
Combinations of SMIs and DOACs often result in relevant DDIs that can be prevented by adjusting the DOAC dosage, separation of administration or switching between anticoagulants.
No takes yet. Share an insight, caveat, or question.
Otten et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: